Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outset Medical, Inc. (NASDAQ: OM) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Outset is a medical technology manufacturer focused on the Tablo Hemodialysis System, and its filings offer detail on financial performance, risk factors, and the business model behind its dialysis platform.
Among the key documents, investors can review Form 10-K annual reports and Form 10-Q quarterly reports, which typically include discussions of product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and liquidity. These filings also reference the risks and uncertainties that could affect Outset’s results and the regulatory environment in which it operates.
Outset’s Form 8-K current reports are particularly relevant for tracking material events. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter financial results and updated or revised revenue guidance. Such filings summarize the nature of the event and incorporate the related press release by reference.
On this page, users can also monitor insider transaction reports on Form 4, proxy statements on Schedule 14A when available, and other submissions that shed light on governance, executive compensation, and ownership changes.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents, highlight notable changes from prior periods, and surface items such as revenue mix, margin commentary, and forward-looking statements. Real-time updates from EDGAR help ensure that new OM filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider reports, are quickly reflected and summarized for easier review.
A holder of common stock in OM has filed a notice of proposed sale under Rule 144. The filer plans to sell 5,375 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of
The securities to be sold were acquired on
Outset Medical insider plans Rule 144 stock sale. A holder of Outset Medical (symbol OM) common stock, identified as Leslie Trigg, filed notice to sell 11,794 shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of
OM received a notice that insider John Brottem plans to sell 9,314 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026 on the NASDAQ market. The filing lists an aggregate market value of $47,682.76 for these shares, compared with 18,153,090 shares of common stock outstanding.
The securities to be sold were acquired on 01/17/2026 through settlement of 17,997 vested restricted stock units as equity compensation for services rendered. The notice also reports that during the prior three months, Brottem sold 388 shares on 11/17/2025 for $1,784.80 and 244 shares on 01/07/2026 for $956.48. By signing, the seller represents they are not aware of undisclosed material adverse information about OM.
BML Investment Partners, L.P.Outset Medical, Inc. common stock on a Schedule 13G. BML disclosed beneficial ownership of 1,705,876 shares of common stock, representing 9.4% of the outstanding class.
BML reported shared voting and dispositive power over all 1,705,876 shares, with no sole voting or dispositive authority. The filing is signed by Braden M. Leonard on behalf of BML Capital Management, LLC, the general partner of BML Investment Partners, L.P., and notes that Leonard is deemed an indirect owner of these shares. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Outset Medical, indicating a passive investment intent.
Outset Medical, Inc. director Karen Prange reported an equity grant in the form of restricted stock units. On January 9, 2026, she was awarded 18,667 RSUs, each representing a contingent right to receive one share of Outset Medical common stock at a price of $0.00 per unit.
The RSUs vest quarterly over three years, conditioned on her continued service with the company through each applicable vesting date. Following this grant, she beneficially owns 18,667 shares of common stock directly.
Outset Medical, Inc. director reports no beneficial ownership. Karen Prange, identified as a director of Outset Medical, Inc. (symbol OM), filed an initial statement of beneficial ownership of securities as of 01/09/2026. The filing states that no securities are beneficially owned, and both the non-derivative and derivative securities tables contain no holdings. The form is filed by a single reporting person and includes a power of attorney authorizing execution of the filing on her behalf.
Outset Medical, Inc. reported that it issued a press release with expected revenue for the fourth quarter and full year ended December 31, 2025, noting that this financial information is preliminary, unaudited and may change as closing and audit processes are completed. The company also furnished an updated investor presentation.
Board member Andrea Saia resigned effective January 9, 2026, and the company stated her departure was not due to any disagreement on operations, policies or practices. The Board appointed Karen Prange as a new independent director and Compensation Committee member, filling the vacancy as a class III director with a term running until the 2026 annual meeting. In connection with her appointment, Prange will receive an initial grant of 18,667 restricted stock units that vest quarterly over three years and an annual grant of 10,667 restricted stock units, subject to the company’s non‑employee director compensation policy.
Outset Medical executive Marc Nash reported a small, tax-related stock sale. On January 7, 2026, he sold 108 shares of Outset Medical common stock at $4.27 per share.
According to the footnote, the sale was required to cover tax withholding obligations tied to 289 shares underlying performance stock units that were earned based on performance criteria as of December 31, 2024 or January 6, 2025 and that vested and were released on January 6, 2025. The transaction was executed as a "sell to cover" and is described as not a discretionary trade by Nash.
After this sale, Nash directly beneficially owns 48,160 shares of Outset Medical common stock.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, sold 224 shares of common stock on 01/07/2026 at a price of $4.27 per share. After this transaction, he beneficially owned 46,271 shares directly.
The filing explains that the sale was a required "sell to cover" transaction to satisfy tax withholding obligations tied to 447 shares of common stock underlying performance stock units that had been earned and vested, and it did not represent a discretionary trade by Brottem.
Outset Medical, Inc. Chair and CEO Leslie Trigg reported a small sale of company stock that was made only to cover taxes. On January 7, 2026, she sold 1,795 shares of common stock at $4.27 per share in a transaction coded “S,” described as a “sell to cover” for tax withholding related to previously earned PSUs. According to the disclosure, this sale was required to satisfy tax obligations and “does not represent a discretionary trade.”
Following the sale, Trigg beneficially owned 119,617 shares of common stock directly, plus 41,666 shares held indirectly through the Trigg 2002 Rev Trust and 584 shares held indirectly through the Trigg Family Trust.